Meeting
2017 ASCO Annual Meeting
PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.
Authors
Johann S. De Bono
The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
Johann S. De Bono , Maha Hussain , Antoine Thiery-Vuillemin , Joaquin Mateo , A. Oliver Sartor , Kim N. Chi , Karim Fizazi , Przemyslaw Twardowski , Neeraj Agarwal , Shahneen Kaur Sandhu , David Olmos , Neal D. Shore , Fred Saad , Sherry Liu , Carsten Dietrich Goessl , Joe Burgents
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02987543
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5091)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5091
Abstract #
TPS5091
Poster Bd #
162b
Abstract Disclosures
Similar Posters
First Author: Charles J. Ryan
Poster
2018 Genitourinary Cancers Symposium
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Charles J. Ryan
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.
First Author: Neal D. Shore